Target Name: WDR62
NCBI ID: G284403
Review Report on WDR62 Target / Biomarker Content of Review Report on WDR62 Target / Biomarker
WDR62
Other Name(s): DKFZp434J046 | C19orf14 | WDR62 variant 1 | WD repeat-containing protein 62 (isoform 2) | WD repeat-containing protein 62 | microcephaly, primary autosomal recessive 2 | WD repeat-containing protein 62 (isoform 1) | WD repeat domain 62 | truncated WDR62 | MCPH2 | DKFZp686G1024 | WDR62_HUMAN | WDR62 variant 2 | WD repeat domain 62, transcript variant 1 | Microcephaly, primary autosomal recessive 2 | FLJ33298 | WD repeat domain 62, transcript variant 2 | MGC166976

Understanding The Role of WDR62 in Cancer and Neurobladder Cancer

WDR62 (Wilms' tumor 62) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed new light on its role in the development and progression of these diseases.

WDR62 is a RNA molecule that is expressed in almost all human tissues and has been implicated in various biological processes. It is a part of the Wnt pathway, a well-known signaling pathway that regulates cell growth, differentiation, and development. The Wnt pathway has been implicated in the development and progression of many diseases, including cancer, and researchers are always looking for new targets to study.

One of the key features of WDR62 is its structure. It is a small molecule that consists of only 18 amino acid residues and has a unique 3D structure that is distinct from other RNA molecules. WDR62 has a single open reading frame and a single exon. It is expressed in almost all human tissues and has been shown to be involved in various signaling pathways.

WDR62 has been shown to be involved in the regulation of cell adhesion and in the development of cancer. It has been shown to play a role in the development of neurobladder cancer, a type of cancer that affects the urinary system. Studies have shown that high levels of WDR62 are associated with the development of neurobladder cancer and that inhibiting its activity may be a useful strategy for treating this disease.

WDR62 has also been shown to be involved in the regulation of cell proliferation. It has been shown to play a role in the regulation of cell proliferation in various tissues and has been shown to be involved in the development of cancer. Studies have shown that high levels of WDR62 are associated with the development of cancer and that inhibiting its activity may be a useful strategy for preventing or treating cancer.

WDR62 has also been shown to be involved in the regulation of gene expression. It has been shown to play a role in the regulation of gene expression in various tissues and has been shown to be involved in the development of cancer. Studies have shown that high levels of WDR62 are associated with the development of cancer and that inhibiting its activity may be a useful strategy for preventing or treating cancer.

In conclusion, WDR62 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed new light on its role in the development and progression of these diseases. Further research is needed to fully understand the role of WDR62 in these diseases and to develop effective treatments.

Protein Name: WD Repeat Domain 62

Functions: Required for cerebral cortical development. Plays a role in neuronal proliferation and migration (PubMed:20890278, PubMed:20729831). Plays a role in mother-centriole-dependent centriole duplication; the function seems also to involve CEP152, CDK5RAP2 and CEP63 through a stepwise assembled complex at the centrosome that recruits CDK2 required for centriole duplication (PubMed:26297806)

The "WDR62 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR62 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX